Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973162 | 0.84 | CA1 (0.50) | MAP2K1CYP3A4CYP1A2CA1CA2 | |
| SCHEMBL819594 | 0.84 | CA1 (0.50) | MAP2K1CYP3A4CYP1A2CA1CA2 | |
| Hydrogen Sulfide SCHEMBL29288364 | 0.81 | CA1 (0.48) | MAP2K1CYP3A4CYP1A2CA1CA2 | |
| SCHEMBL10338061 | 0.81 | TSHR (0.50) | MAP2K1CYP3A4CYP1A2CA1CA2 | |
| SCHEMBL25842787 | 0.79 | HTT (0.46) | MAP2K1CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL689260 | 0.78 | CYP1A1 (0.42) | CYP3A4CYP1A2CYP2C9CYP2C19JAK2 | |
| SCHEMBL21896646 | 0.76 | MAP2K1 (0.41) | MAP2K1CYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL65699 | 0.75 | JAK2 (0.54) | CYP3A4CYP1A2CYP2C9CYP2C19JAK2 | |
| SCHEMBL29349435 | 0.75 | JAK2 (0.54) | CYP3A4CYP1A2CYP2C9CYP2C19JAK2 | |
| SCHEMBL5749081 | 0.75 | KDM4E (0.44) | MAP2K1CYP3A4CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091746-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION (US) | 2023-05-25 | — | — | WO | disclosed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-5545744-A | Cyano naphthalene compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5545744-A | Cyano naphthalene compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5498727-A | Preparation of benzindole compounds from naphthalene compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| US-5498727-A | Preparation of benzindole compounds from naphthalene compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| WO-1996002502-A1 | PREPARATION OF BENZINDOLE COMPOUNDS FROM NAPHTHALENE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996002502-A1 | PREPARATION OF BENZINDOLE COMPOUNDS FROM NAPHTHALENE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | MAP2K1 2093/4885CYP3A4 95/4885CYP1A2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.